EXICURE, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31)
EXICURE, INC. (XCUR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) of $21.01 million as of 2018-01-01, per its 10-Q filed 2019-08-08.
Discontinued › Notes
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 · last filed 2020-03-10
- 2018-01-01: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $21.01M.
- 2017-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $21.01M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) |
|---|---|
| 2018-01-01 | $21.01M 10-Q · filed 2019-08-08 |
| 2017-12-31 | $21.01M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |